Allianz Asset Management Gmb H Adc Therapeutics Sa Transaction History

Allianz Asset Management Gmb H

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$5.96 - $14.99 $36,058 - $90,689	-6,050 Reduced 8.92%	61,760 $491,000
Q1 2022 May 13, 2022	BUY	$13.28 - $20.03 $129,878 - $195,893	9,780 Added 16.85%	67,810 $996,000
Q4 2021 Feb 11, 2022	BUY	$19.29 - $31.51 $190,199 - $310,688	9,860 Added 20.47%	58,030 $1.18 Million
Q3 2021 Nov 10, 2021	BUY	$20.45 - $30.0 $565,544 - $829,650	27,655 Added 134.8%	48,170 $1.31 Million
Q2 2021 Aug 16, 2021	SELL	$20.38 - $27.04 $857,488 - $1.14 Million	-42,075 Reduced 67.22%	20,515 $500,000
Q4 2020 Feb 16, 2021	BUY	$25.26 - $38.02 $1.58 Million - $2.38 Million	62,590 New	62,590 $2 Million

55.1M

82.7K

31.5K

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $175M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.